Press Releases

BOSTON--(BUSINESS WIRE)--

Natixis Global Associates (NGA), named by Financial Research Corp. as the fastest-growing mutual fund complex in 2006 and 2007(1), today announced the launch of the Delafield Select Fund. The Fund is a concentrated portfolio of approximately 25 small- and mid-cap value stocks managed for capital appreciation.

The Delafield Select Fund is managed by veteran portfolio managers Vincent Sellecchia, J. Dennis Delafield, Charles Neuhauser and Donald Wang. Mr. Sellecchia and Mr. Delafield have also co-managed the Delafield Fund since its inception in 1993. Delafield Asset Management is a division of Reich & Tang Asset Management, the investment manager for the Fund.

The Fund has been launched after acquiring the assets and liabilities of the Reich & Tang Concentrated Portfolio, L.P. ("Concentrated, L.P."). Mr. Sellecchia has been a manager of the Concentrated, L.P. since its inception in 1998; Mr. Neuhauser and Mr. Wang since 2003; and Mr. Delafield since 2005. The Delafield Select Fund has a substantially similar investment strategy to the Concentrated, L.P. but is a registered '40 Act mutual fund and offers A, C and Y shares.

"The Delafield Asset Management team has produced strong long-term results and we are pleased to be able to introduce their capabilities to the retail broker-dealer channel," said David Giunta, president of Natixis Global Associates. "The Delafield Select Fund is a great addition to our product line-up and will provide our investors with another solid offering in the small-mid cap equity category."

"We are pleased to partner with Natixis on this initiative," said Mr. Sellecchia. "This is an ideal opportunity for us to reach a broader pool of investors and our existing L.P. interest holders will benefit from enhanced infrastructure and shareholder services provided through Natixis Global Associates."

About Reich & Tang Asset Management

Reich & Tang Asset Management is comprised of three operating groups:

Delafield Asset Management provides value equity strategies to institutional and high net worth clients.

Reich & Tang Funds specializes in the investment of short-term liquid assets through a family of money market funds and similar portfolios.

Global Investment Advisors offers globally diversified yield-enhanced fixed income portfolios to institutional clients.

About Natixis Global Associates

Natixis Global Associates (NGA) is the distribution arm of Natixis Global Asset Management. NGA works on a consultative basis from its 12 worldwide offices, tailoring the expertise of its managers to meet the investment objectives of local clients. In the U.S., Natixis Global Associates includes Natixis Distributors, L.P. (member FINRA) and Natixis Asset Management Advisors, L.P. (a registered investment advisor). Both are located at 399 Boylston Street, Boston, MA 02116. www.ga.natixis.com

About Natixis Global Asset Management

Natixis Global Asset Management is one of the 15 largest asset managers in the world(2) based on assets under management. Its affiliated asset management companies provide investment products that seek to enhance and protect the wealth and retirement assets of both institutional and individual investor clients. Its proprietary distribution network helps package and deliver its affiliates' products around the world. Natixis Global Asset Management brings together the expertise of multiple specialized investment managers based in Europe, the United States and Asia to offer a wide spectrum of equity, fixed income and alternative investment strategies.

Headquartered in Paris and Boston, Natixis Global Asset Management's assets under management totaled $890 billion (EUR 564 billion) as of June 30, 2008. Natixis Global Asset Management is part of Natixis, the investment and projects bank of the Banque Populaire and Caisse d'Epargne groups. Its affiliated investment management firms and distribution and service groups include: AEW Capital Management; AlphaSimplex Group; Capital Growth Management; Caspian Capital Management; Gateway Investment Advisers; Hansberger Global Investors; Harris Alternatives; Harris Associates; Loomis, Sayles & Co.; Natixis Global Associates; Reich & Tang Asset Management; Snyder Capital Management; Vaughan Nelson Investment Management; and Westpeak Global Advisors. In addition to the U.S. firms, Natixis Global Asset Management includes four principal affiliates based in Paris: Natixis Asset Management, Natixis Multimanager, AEW Europe and Natixis Epargne Financiere.

For more complete information about the Delafield Select Fund including a prospectus detailing charges and expenses, please contact your financial representative, or call Natixis Distributors, L.P. at 800-862-4863. Investors should consider a fund's objective, risks and expenses carefully before investing. This and other information can be found in the fund's prospectus. Please read the prospectus carefully before you invest or send money.

(1) As measured by the ratio of net flows to assets. Among other fund firms with $10 billion or more in assets.

(2) Cerulli Quantitative Update: Global Markets 2008, based on Dec. 31, 2007 AUM of $870 billion.

Source: Natixis Global Associates

KANSAS CITY, Mo.--(BUSINESS WIRE)--

Interstate Bakeries Corporation (IBC) (OTC: IBCIQ) announced today that it filed an amended Plan of Reorganization and related Disclosure Statement with the U.S. Bankruptcy Court for the Western District of Missouri on October 4, 2008.

The filing of the Plan of Reorganization and related Disclosure Statement was made in connection with the plan funding commitments, announced on September 12, 2008, from an affiliate of Ripplewood Holdings L.L.C. (the "Equity Investor") and from Silver Point Finance, LLC, and Monarch Master Funding Ltd. As previously announced, the funding commitments form a basis for IBC to emerge from Chapter 11 as a stand-alone company, under the Plan of Reorganization filed with the Bankruptcy Court.

The Plan of Reorganization and related Disclosure Statement filed on October 4, 2008 reflect a substantially impaired recovery for pre-petition senior secured creditors. For general unsecured creditors and equity security holders, the amended Plan of Reorganization and related Disclosure Statement reflect no recovery, although on October 3, 2008 the Company and its pre-petition secured creditors reached a compromise with the Official Committee of Unsecured Creditors appointed in the cases. As a result of the compromise, the Official Committee of Unsecured Creditors withdrew its previously filed objection to the Company's efforts to obtain Bankruptcy Court approval of the plan funding commitments and agreed to support the Company's Plan of Reorganization as it will be subsequently amended to reflect the compromise. The Plan of Reorganization has the support of approximately 53.8% of the pre petition secured debt holders.

The compromise reached with the Official Committee of Unsecured Creditors, which is subject to definitive documentation, provides for, among other things, the establishment of a creditors' trust upon IBC's emergence from Chapter 11 for the benefit of the general unsecured creditors. The creditors' trust will be funded through a cash payment of $5 million. Costs of administering the trust will be paid from the trust assets. The creditors' trust will also receive rights to pursue certain litigation claims at the expense of the creditors' trust. Finally, the creditors' trust will potentially receive a cash payment upon a future liquidity event with such payment based on the increase, if any, in value of a 3% equity ownership stake in the reorganized IBC in excess of 150% of the investment equity value paid by the Equity Investor. There can be no assurance that the litigation claims or the potential cash payment described above will result in any distributable value for general unsecured creditors.

The filing of the Plan of Reorganization and related Disclosure Statement is an important step in IBC's ongoing efforts to emerge from Chapter 11. Going forward, the Company intends to amend the filed Plan of Reorganization and related Disclosure Statement to reflect the compromise reached with the Official Committee of Unsecured Creditors and seek Bankruptcy Court approval of the amended Disclosure Statement and confirmation of the amended Plan of Reorganization through the Chapter 11 process.

About the Company

Interstate Bakeries Corporation is one of the nation's largest commercial bakers and distributors of fresh-baked bread and sweet goods, sold under various brand names, including Wonder(R), Merita(R), Home Pride(R), Baker's Inn(R), Hostess(R), Drake's(R), and Dolly Madison(R). The Company is headquartered in Kansas City, Missouri.

Interstate Bakeries Corporation filed for bankruptcy protection on September 22, 2004, citing liquidity issues resulting from declining sales, a high fixed-cost structure, excess industry capacity, rising employee healthcare and pension costs, and higher costs for ingredients and energy. The Company continues to operate its business in the ordinary course as a debtor-in-possession.

About Ripplewood Holdings L.L.C.

Based in New York, Ripplewood Holdings L.L.C. is a leading private equity firm established in 1995 by Timothy C. Collins. Through five institutional private equity funds managed by Ripplewood, the firm has invested over $4.5 billion of equity in transactions in the U.S., Asia, Europe and the Middle East.

Forward-Looking Statement

Some information contained in this press release may be forward-looking statements within the meaning of the federal securities laws. These forward-looking statements are not historical in nature and include statements that reflect, when made, the Company's views with respect to current events and financial performance. These forward-looking statements can be identified by forward-looking words such as "may," "will," "expect," "intend," "anticipate," "believe," "estimate," "plan," "could," "should" and "continue" or similar words. These forward-looking statements may also use different phrases. All such forward-looking statements are and will be subject to numerous risks and uncertainties, many of which are beyond our control that could cause actual results to differ materially from such statements. Factors that could cause actual results to differ materially include, without limitation: the ability of the Company to continue as a going concern; the ability of the Company to obtain approval of the revised plan of organization and related financing agreements and fees from the bankruptcy court on a timely basis; the Company's ability to obtain ratification from its unionized workforce of the modifications to their collective bargaining agreements contemplated by the revised plan of reorganization; the terms of any reorganization plan ultimately confirmed; the Company's ability to implement its business plan; the ability of the Company to operate pursuant to the covenants, terms and certifications of its DIP financing facility, as amended and restated; the ability of the Company to obtain court approval with respect to motions in the Chapter 11 proceeding filed by it from time to time; risks associated with third parties seeking and obtaining court approval for the appointment of a Chapter 11 trustee or to convert the Chapter 11 proceeding to a Chapter 7 proceeding; risks associated with cost increases in materials, ingredients, energy and employee wages and benefits; risks associated with the Company's restructuring activities, including the risks associated with achieving the desired savings; the Company's ability to successfully reject unfavorable contracts and leases; the duration of the Chapter 11 process; the ability of the Company to obtain and maintain adequate terms with vendors and service providers; the potential adverse impact of the Chapter 11 proceeding on the Company's liquidity or results of operations; the Company's ability to operate its business under the restrictions imposed by the Chapter 11 process; the instructions, orders and decisions of the bankruptcy court and other effects of legal and administrative proceedings, settlements, investigations and claims; the significant time that will be required by management to implement the revised plan of reorganization; risks associated with product price increases, including the risk that such actions will not effectively offset inflationary cost pressures and may adversely impact sales of the Company's products; the effectiveness of the Company's efforts to hedge its exposure to price increases with respect to various ingredients and energy; the ability of the Company to attract, motivate and/or retain key executives and employees; changes in our relationship with employees and the unions that represent them; successful implementation of information technology improvements; increased costs and uncertainties with respect to a defined benefit pension plan to which we contribute; costs associated with increased contributions to single employer, multiple employer or multi-employer pension plans; the impact of any withdrawal liability arising under the Company's multi-employer pension plans as a result of prior actions or current consolidations; the effectiveness and adequacy of our information and data systems; changes in general economic and business conditions (including in the bread and sweet goods markets); changes in consumer tastes or eating habits; acceptance of new product offerings by consumers and the Company's ability to expand existing brands; the performance of the Company's recent and planned new product introductions, including the success of such new products in achieving and retaining market share; the effectiveness of advertising and marketing spending; any inability to protect and maintain the value of the Company's intellectual property; future product recalls or food safety concerns; actions of competitors, including pricing policy and promotional spending; bankruptcy filings by customers; costs associated with environmental compliance and remediation; actions of governmental entities, including regulatory requirements; the outcome of legal proceedings to which we are or may become a party; business disruption from terrorist acts, our nation's response to such acts and acts of war; and other factors. These statements speak only as of the date of this press release, and we disclaim any intention or obligation to update or revise any forward-looking statements to reflect new information, future events or developments or otherwise, except as required by law. We have provided additional information in our filings with the SEC, which readers are encouraged to review, concerning other factors that could cause actual results to differ materially from those indicated in the forward-looking statements.

Similarly, these and other factors, including the terms of any reorganization plan ultimately confirmed, can affect the value of the Company's various pre-petition liabilities, common stock and/or other equity securities. No assurance can be given as to what values, if any, will be ascribed in the Chapter 11 proceeding to each of these liabilities and/or securities. Accordingly, the Company urges that the appropriate caution be exercised with respect to existing and future investments in any of these liabilities and/or securities.

Source: Interstate Bakeries Corporation

ZURICH, Switzerland--(BUSINESS WIRE)--

Sonnenschein Nath & Rosenthal LLP today announced that Heinz Bloch and Robert Schlup, two of Europe's most prominent hotel lawyers, have joined the law firm as partners in Zurich, Switzerland, where it is opening a new office. Previously, Bloch and Schlup operated Bloch & Partner, a boutique law firm in Zurich. Also moving to Sonnenschein with them is associate Ion Eglin.

"Heinz and Robert have built a world-class hospitality practice, with several of the most prominent hotel owners and operators in the industry among their clients," said Richard F. "Rick" Ross, chair of Sonnenschein's Hotels & Resorts Global Practice. "They bring a combined 55 years of hotel industry legal experience to our team, and they will serve as outstanding ambassadors for our practice and for the firm in Europe and beyond."

Bloch and Schlup have a broad international practice based in Zurich and have been involved in hotel and resort projects around the globe, including regular engagements across Europe, Russia, the Middle East and Central Asia. They represent hotel owners and developers, private investors, financial institutions and hotel management companies worldwide on a variety of matters, from mergers and acquisitions, real estate transactions and joint ventures to management contracts and lease transactions. Prior to creating Bloch & Partner, Bloch was development director and counsel for Hilton International and Swissotel. In addition, Schlup is the author of a Ph.D. thesis on hotel management agreements.

"Rick and his team have a preeminent reputation in the United States and around the world for their successful, multi-dimensional representation of a broad range of clients," stated Bloch. "I am looking forward to working with them to achieve the goal of European and global leadership in our field."

Added Schlup, "Sonnenschein is one of the foremost law firms serving the hotel and resort industry. It also provides an excellent platform on which we can draw to serve a wider range of our clients' transactional needs, including great depth in practice areas such as real estate and corporate."

Sonnenschein's Zurich office will open in the space previously occupied by Bloch & Partner at Seestrasse 39 in Kusnacht, Zurich. In addition to the hospitality industry, it will serve the international business community by offering a broad range of general corporate and commercial legal services. Fully integrated with the firm's other offices in Brussels, Belgium, and 13 U.S. cities, the Zurich office will represent foreign investors in Switzerland and other countries in Europe and will be a gateway for European clients doing business in the United States.

"The opportunity to attract such talented lawyers as Heinz and Robert to the firm made opening a Zurich office an easy decision for us," said Elliott I. Portnoy, Sonnenschein chairman. "Given Zurich's prominent position in the financial services industry, our vision is to grow the office beyond our hotel expertise and to add practices that would provide strategic benefits to the firm in this market."

For more information, visit www.sonnenschein.com.

Source: Sonnenschein Nath & Rosenthal LLP

LONDON, UNITED KINGDOM -- (MARKET WIRE) -- 10/06/08 -- Reportlinker.com announces that a new market research report related to the Pharmaceutical industry industry is available in its catalogue.

Production, market and benchmarking of Carnitine in China

http://www.reportlinker.com/p096340/Production-market-and-benchmarking-of-Carnitine-in-China.html

L-Carnitine, a natural and water soluble nutrient that can be produced by human body and also can be obtained from muscles, is an indispensable factor in the metabolism of fat and has many essential functions in human body.

These years, the role of Chinese L-Carnitine industry in the world has become more and more important. Although L-Carnitine has been discovered for over a century and has developed quite well in Switzerland, Italy, US and Japan, the production and industrial application of L-Carnitine in China just began 10-15 years ago. However, the L-Carnitine industry develops rapidly in China. At the moment, China's L-Carnitine is competitive both at home and aboard thanks to its low price and good quality. 12 Chinese producers are active in production of L-Carnitine currently. Their total output of L-Carnitine in 2007 reached 1,408 tonnes, 34.94% of which was exported. And only small quantity of L-Carnitine is imported.

What will the role of China's L-Carnitine industry be in the global market? Will the export volume grow larger in the future? This report will answer these questions.

Because of the Beijing Olympic Games and the rising prices of some major raw materials, the price of L-Carnitine has been growing since the end of 2007 or early 2008, and it has been 20%-40% higher than that in the past 3 years. How does it influence domestic L-Carnitine production and the export? Can domestic L-Carnitine producers earn considerable profit under the current situation? CCM will give a detailed analysis in this report.

Driven by the huge profits and positive market prospects, many Chinese L-Carnitine manufacturers expand their capacities. It is forecasted that production capacity of L-Carnitine in China will have a sharp rise in the next few years. The competition between L-Carnitine manufacturers in China will be increasingly apparent. Moreover, with the development of oversea producers, the competitions among countries will grow increasingly intense. Compared with some internationally well-known L-Carnitine producers such as Lonza, are there any other competitive advantages in major domestic L-Carnitine producers apart from low production cost? Can they still earn satisfying profit when facing the international L-Carnitine producing giants?

L-Carnitine is mainly used in health food and feed in China. As China is a country with huge potential market for health food and feed and more and more Chinese people realize the importance of health food, the consumption of L-Carnitine will be even larger in China. Are there any other potential large consumption fields of L-Carnitine in China? What is the future of L-Carnitine production in China? This report will also reveal the current situations of L-Carnitine application and demand in China.

Executive summary
Methodology and definitions
I Production and market information of Carnitine in China
I-1 Brief history of Carnitine production in China
I-2 Current production situation of Carnitine in China
I-2.1 Summary of manufacturers
I-2.2 Summary of production and market
I-3 Development of Carnitine derivatives in China
- Acetyl L-Carnitine
- Tartrate L-Carnitine
- Fumarate L-Carnitine
- Other important and/or new Carnitine derivatives
I-4 Production technology of Carnitine in China
I-5 Situation of researchers and their achievement in China
I-6 Supply of major raw materials of Carnitine in China
I-6.1 Brief introduction to raw materials involved in Carnitine production
I-6.2 Current supply of major raw materials of Carnitine in China
I-7 Import and export of Carnitine and its derivatives in the recent three
 years
I-7.1 Import situation of Carnitine and its derivatives
I-7.2 Export situation of Carnitine and its derivatives
I-8 Consumption pattern of Carnitine in China
I-8.1 Consumption pattern
I-8.2 End user list
I-9 Future forecast
I-9.1 Key factors and driven forces for the development of Carnitine in
 China
I-9.1.1 Macro economics
I-9.1.2 Policies
I-9.1.3 Demand from end use fields
I-9.1.4 Health situation of China's people
I-9.2 Future forecast on Carnitine in the Next 5-10 Years
I-10 Conclusion
II Benchmarking of Carnitine
II-1 Introduction to this work
II-2 Theoretical Analysis
II-2.1 Chemical synthesis method
II-2.1.1 Model 1
II-2.1.2 Model 2
II-2.2 Enzymatic conversion method
II-2.3 Carnitine derivatives
II-2.3.1 Acetyl L-Carnitine
II-3 Verification and profit estimation of Chinese manufacturers
II-3.1 Northeast Pharmaceutical Group Co., Ltd. (NEPG)
II-3.1.1 Survey and site visit summary
II-3.1.2 Profit estimation of Carnitine
II-3.2 Shenyang Koncepnutra Co., Ltd.
II-3.2.1 Survey and site visit summary
II-3.2.2 Profit estimation of Carnitine
II-3.3 Shenzhen Asiatop Carnitine Technology Co., Ltd.
II-3.3.1 Survey and site visit summary
II-3.3.2 Profit estimation of Carnitine
II-3.4 Lonza
II-3.4.1 Survey summary
II-3.4.2 Profit estimation of Carnitine
II-3.5 Comparison between Lonza and some domestic Carnitine producers
III Appendix: profiles of major producers in China
III-1 Shenyang Koncepnutra Co., Ltd.(Shenyang Dongyu Fine Chemicals Co.
 Ltd.)
......
III-12 Shanghai Kechang Fine Chemicals Co. Ltd.

LIST OF TABLES

Table I-1-1 Development history of L-Carnitine in China
Table I-1-2 Development history of L-Carnitine in the world
Table I-2.1-1 Basic info of L-Carnitine producers in China, 2008
Table I-2.1-2 Capacity and output of L-Carnitine producers in China, 2008
Table I-2.1-3 Output and capacity breakdown by regions, 2008
Table I-2.2-1 Quoted price of L-Carnitine from different manufacturers,
 Jul-2008, RMB/kg
Table I-2.2-2 Quoted price of L-Carnitine and its derivatives from Zhejiang
 Jiashan, unit: RMB/kg
Table I-3-1 Specification of Acetyl-L-Carnitine from NEPG, 2008
Table I-3-2 Output of Acetyl-L-Carnitine (HCl) in China, 2007
Table I-3-3 Specification of L-Carnitine tartrate from NEPG, 2008
Table I-3-4 Output of L-Carnitine Tartrate in China, 2007
Table I-3-5 Specification of L-Carnitine Fumarate from NEPG, 2008
Table I-3-6 Output of L-Carnitine Fumarate in China, 2007
Table I-3-7 Specification of DL-Carnitine Orotate from Shenyang Koncepnutra,
 2008
Table I-3-8 Specification of L-Carnitine Orotate from Shenyang Koncepnutra,
 2008
Table I-4-1 Comparison of production technologies of Carnitine in China
Table I-5-1 Research situation on the production of Carnitine in China in
 recent years
Table I-6.1-1 Nature Sources of L-Carnitine
Table I-6.2.1-1 Major epichlorohydrin Manufacturers in China, 2008
Table I-6.2.1-2 Supply situation of Epichlorohydrin in China, 2005-2007,
 tonnes
Table I-6.2.1-3 Price change of Epichlorohydrin in China in recent years,
 RMB/t
Table I-6.2.1-4 Consumption Pattern of Epichlorohydrin in China
Table I-6.2.2-1 Major timethylamine manufacturers in China, 2008
Table I-6.2.2-2 Trimethylamine consumption pattern in China, 2008
Table I-6.2.3-1 Major producers of sodium cyanide in China, 2008
Table I-6.2.3-2 Export and import of sodium cyanide in recent two years, kt
Table I-6.2.3-3 Consumption pattern of sodium cyanide in China, 2008
Table I-7.1-1 Import of Carnitine in 2005-2007 (Quantity (kg); Price
 (USD/kg))
Table I-7.1-2 Origin countries of Carnitine in 2005-2007 (Quantity (kg);
 Price (USD/kg))
Table I-7.1-3 Importers of Carnitine in 2005-2007 (Quantity (kg); Price
 (USD/kg))
Table I-7.2-1 Export price of Carnitine in 2005 (Quantity (kg); Price
 (USD/kg))
Table I-7.2-2 Export price of Carnitine in 2006 (Quantity (kg); Price
 (USD/kg))
Table I-7.2-3 Export price of Carnitine in 2007 (Quantity (kg); Price
 (USD/kg))
Table I-7.2-4 Exporter of Carnitine in 2005 (Quantity (kg); Price (USD/kg))
Table I-7.2-5 Exporter of Carnitine in 2006 (Quantity (kg); Price (USD/kg))
Table I-7.2-6 Exporter of Carnitine in 2007 (Quantity (kg); Price (USD/kg))
Table I-7.2-7 Export destination of Carnitine in 2005 (Quantity (kg); Price
 (USD/kg))
Table I-7.2-8 Export destination of Carnitine in 2006 (Quantity (kg); Price
 (USD/kg))
Table I-7.2-9 Export destination of Carnitine in 2007 (Quantity (kg); Price
 (USD/kg))
Table I-7.2-10 Export situation of Chinese manufacturers in 2005 (Quantity
 (kg); Price (USD/kg))
Table I-7.2-11 Export situation of Chinese manufacturers in 2006(Quantity
 (kg); Price (USD/kg))
Table I-7.2-12 Export situation of Chinese manufacturers in 2007(Quantity
 (kg); Price (USD/kg))
Table I-8.1-1 Applications of L-Carnitine and its derivates in medicines,
 foods and cosmetics
Table I-8.1-2 Applications of L-Carnitine in feeds
Table I-8.2-1 List of some L-Carnitine end users in food area in China, 2008
Table I-8.2-2 List of some L-Carnitine end users in feed area in China, 2008
Table I-8.2-3 Part of L-Carnitine pharmaceutical producers registered in
 SFDA, 2008
Table I-9.1.2-1 Specification regulated in National Standards for Food
 Additive L-Carnitine (base), GB 17787-1999
Table I-9.1.2-2 Specification of L-Carnitine base regulated in USP26 and EP
Table I-9.1.2-3 Specifications of feed additive L-Carnitine regulated in
 NY/T 1028-2006
Table I-9.1.2-4 Using fields and usage levels of L-Carnitine or its
 derivatives specified in GB2760-1996/GB14880-1994
Table I-9.1.2-5 Export rebate for the HS code 29239000 involved Carnitine
Table I-9.1.3-1 Output of feed in China, 2000-2007, tonnes
Table I-9.1.4-1 Top 10 causes of death in China in 2007
Table I-9.2.1-1 Assumptions on the growth of the market size of L-Carnitine
 in China, 2008-2018
Table II-2.1.1-1 Yield rate of each reaction of model 1
Table II-2.1.1-2 Estimation on raw material consumption for model 1
Table II-2.1.2-1 Yield rate of each reaction of model 2
Table II-2.1.2-2 Estimation on raw material consumption for model 2
Table II-2.2-1 Estimation on raw material consumption for enzymatic
 conversion method
Table II-2.3.1-1 Estimation on raw material consumption for Acetyl
 L-Carnitine
Table II-3.1.2 -1 Estimation on raw material consumption of L-Carnitine
 in NEPG in July 2008
Table II-3.1.2-2 Estimation on manufacturing cost of L-Carnitine in NEPG
 in July 2008
Table II-3.1.2-3 Estimation on the total production cost in NEPG in July
 2008 (Unit: RMB/kg)
Table II-3.1.2-4 Estimation on the profit of L-Carnitine in NEPG in July
 2008
Table II-3.2.2-1 Estimation on raw material consumption of L-Carnitine in
 Shenyang Kongcepnutra in July 2008
Table II-3.2.2-2 Estimation on manufacturing cost of L-Carnitine in Shenyang
 Kongcepnutra in July 2008
Table II-3.2.2-3 Estimation on the total production cost in Shenyang
 Kongcepnutra in July 2008 (Unit: RMB/kg)
Table II-3.2.2-4 Estimation on the profit of L-Carnitine in Shenyang
 Kongcepnutra in July 2008
Table II-3.3.2 -1 Estimation on raw material consumption of L-Carnitine in
 Shenzhen Asiatop in July 2008
Table II-3.3.2-2 Estimation on manufacturing cost of L-Carnitine in Shenzhen
 Asiatop in July 2008
Table II-3.3.2-3 Estimation on the total production cost in Shenzhen Asiatop
 in July 2008 (Unit: RMB/kg)
Table II-3.3.2-4 Estimation on the profit of L-Carnitine in Shenzhen Asiatop
 in July 2008
Table II-3.4.2-1 Estimation on raw material consumption of L-Carnitine in
 Lonza in July 2008
Table II-3.4.2-2 Estimation on the total production cost in Lonza in July
 2008 (Unit: EUR/kg)
Table II-3.5-1 Comparison between Lonza and some domestic Carnitine
 producers in July 2008
Table III-3-1 Prices of major products in Zhejiang Jiashan in July 2008
Table III-6-1 Prices of major products in Zhangjiagang Xinyu in July
 2008(RMB/t)
Table III-7-1 Prices of major products in Shenzhen Asiatop(RMB/kg)
Table III-10-1 Prices of major products in Hubei Hongjing(RMB/kg)
Table III-12-1 Quoted price of Shanghai Kechuang, Jul 2008(RMB/kg)

LIST OF FIGURES
Figure I-2.2-1 Output breakdown by species in 2007, tonnes, %
Figure I-8.1-1 L-Carnitine as transporter of fatty acid and the metabolite
 waste in the metabolism of fat in animal cells
Figure I-8.1-2 Apparent consumption of L-Carnitine and its derivative in
 China, 2003-2007, tonnes
Figure I-8.1-3 Consumption pattern of L-Carnitine and its derivatives in
 China, 2007, tonnes, %
Figure I-9.1.1-1 GDP growth of China in the past 8 years
Figure I-9.1.1-2 Exchange rate of RMB against USD
Figure I-9.1.1-3 Exchange rate of RMB against EU and 100 Yen in recent years
Figure I-9.1.3-1 Production value of health food in China, 2000-2007,
 million yuan
Figure I-9.1.4-1 Populations of overweight adults and obesity adults in
 China
Figure I-9.1.4-2 Overweight & obesity rate of adults in China
Figure I-9.2.1-1 Future demand of L-Carnitine in China, 2008-2018, tonnes
Figure I-9.2.2-1 Future output of L-Carnitine in China, 2008-2018, tonnes
Figure I-9.2.2-2 Future export of L-Carnitine in China, 2008-2018, tonnes
Figure II-2.1.1-1 Flow chart of model 1
Figure II-2.1.2-1 Flow chart of model 2
Figure II-2.2-1 Flow chart of enzymatic conversion method
Figure II-2.3.1-1 Flowchart of Acetyl L-Carnitine
Figure II-3.1.1-1 Flowchart of chemical separation of D,L-Carnitine to
 L-Carnitine in Shenzhen Asiatop
Figure II-3.3.1-1 Flowchart of chemical separation of D,L-Carnitine to
 L-Carnitine in Shenzhen Asiatop
Figure II-3.3.1-2 Flowchart of chemical synthesis Acetyl-L-Carnitine (ALC)
 from L-Carnitine in Shenzhen Asiatop
Figure II-3.4.1 Flowchart of L-Carnitine production in Lonza

Shenyang Koncepnutra Co., Ltd.;Liaoning Northeast Pharmaceutical Group; Zhejiang Jiashan Chengda Pharm & Chem Co., Ltd.; Shaanxi East-Star Biochemical Technology Co., Ltd.; Wuhan Dongfang Liwei Biotechnology Co., Ltd.

To order this report:

Production, market and benchmarking of Carnitine in China

http://www.reportlinker.com/p096340/Production-market-and-benchmarking-of-Carnitine-in-China.html

More market research reports here!

Contacts:
Reportlinker.com
Nicolas
US: (805) 652-2626 or Intl: +1-805-652-2626
Email: nbo@reportlinker.com

PRINCETON, NJ -- (MARKET WIRE) -- 10/06/08 -- Educational Testing Service (ETS) and Dale Carnegie® Training of Central and Southern New Jersey are jointly convening a special executive roundtable discussion titled, "Employee Engagement: Senior Leadership's Role in Successful Execution."

Who:      Kurt Landgraf, president and CEO, ETS
          Howard Stoeckel, president and CEO, Wawa, Inc.
          Peter Handal, president and CEO, Dale Carnegie & Associates, Inc.

What:     All three speakers will discuss the critical importance and
          business benefits of having employees "engaged" and the direct
          connection to profitability, productivity, employee retention,
          customer engagement, and employee safety. They will also discuss
          the strategies they have implemented to address this issue, and
          the direct benefits each has seen to their bottom-line.

When:     Wednesday, October 8, 2008

Time:     8 a.m. - 10 a.m.

Location: ETS Rosedale Campus, Chauncey Conference Center (Mallard Room)

"We wanted to provide a forum for the New Jersey business community to explore the strategies and challenges of employee engagement," explains Anita Zinmeister, president, Dale Carnegie Training of Central and Southern New Jersey. "In today's challenging economic and competitive workplace, fully engaging employees at all levels is critical for any organization to meet their objectives and build a robust future."

This limited seating, complimentary event is only open to CEOs, COOs and senior level executives. A continental breakfast will be included. To R.S.V.P., please contact Nicky Oliver at (609) 324-9200.

Media interested in attending should contact Jason Baran at (609) 683-2428 or jbaran@ets.org.

About ETS

ETS is a nonprofit institution with the mission to advance quality and equity in education by providing fair and valid assessments, research and related services for all people worldwide. In serving individuals, educational institutions and government agencies around the world, ETS customizes solutions to meet the need for teacher professional development products and services, classroom and end-of-course assessments, and research-based teaching and learning tools. Founded in 1947, ETS today develops, administers and scores more than 50 million tests annually in more than 180 countries, at over 9,000 locations worldwide. Additional information is available at www.ets.org.

About Dale Carnegie Training

Dale Carnegie Training works with organizations as well as middle market and large corporations to produce measurable business results by improving the performance of employees with emphasis on leadership, sales, team member engagement, customer service, presentations, process improvement and other essential management skills. Recently identified by The Wall Street Journal as one of the top 25 high-performing franchises, the Dale Carnegie Training programs are available in more than 25 languages throughout the entire United States and in more than 75 countries. Dale Carnegie includes as its clients 400 of the Fortune 500 companies. Approximately 7 million people have experienced Dale Carnegie Training.

Dale Carnegie Training's corporate specialists work with individuals, groups and organizations to design solutions that unleash your employees' potential, enabling your organization to reach the next level of performance. Dale Carnegie Training offers public courses, seminars and workshops, as well as in-house customized training, corporate assessments, online reinforcement and one-on-one coaching. For more information, please visit www.dalecarnegie.com.